Browse > Article

Antihypertensive Effect of Amlodipine Adipate, a Novel Salt of Amlodipine, in Hypertensive Rat Models  

Lee, Byung-Ho (Medicinal Science Division, Korea Research Institute of Chemical Technology)
Seo, Ho-Won (Medicinal Science Division, Korea Research Institute of Chemical Technology)
Chae, Myeong-Yun (R&D Center of Pharmaceuticals, CJ Corp.)
Yeon, Kyu-Jeong (R&D Center of Pharmaceuticals, CJ Corp.)
Publication Information
Biomolecules & Therapeutics / v.12, no.1, 2004 , pp. 19-24 More about this Journal
Abstract
The vascular relaxant effect of amlodipine adipate, a new salt of amlodipine, was evaluate in isolated rat aorta, and compared with that of amlodipine besylate. Furthermore, antihypertensive effects were measured in hypertensive rat models, such as spontaneously hypertensive rats (SHR) and rena1 hypertensive rats (RHR). Amlodipine adipate concentration-dependently inhibited $Ca^{2+}$-induced contraction of rat aorta with a very slow onset of action (reached its maximum at 3.5 h;$IC_{50}$: 3.76 nM), having a pattern and a potency similar to those of amlodipine besylate ($IC_{50}$: 4.01 nM). In SHR and RHR, orally administered amlodipine adipate produced a dosedependent and long-lasting (>10-24 h) antihypertensive effect ($ED_{20}$: 2.48 and 1.57 mg/kg, respectively), with a pattern and a potency similar to those of amlodipine besylate ($ED_{20}$: 2.50 and 1.99 mg/kg in SHR and RHR, respectively). These results suggest that amlodipine adipate is a potent and long-lasting antihypertensive agent and that its antihypertensive effect is not significantly different to that of amlodipine besylate.
Keywords
antihypertensive effect; amlodipine; adipate; calcium antagonist; SHR; RHR;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Burges, R. A., Gardiner, D. G., Gwilt, M., Higgins, A. J., Blackburn, K. J., Campbell, S. F., Cross, P. E. and Stubbs, J. K. (1987). Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro: evidence for voltage modulation of vascular dihydropyridine receptors J. Cardiavasc. Pharmacal. 9, 110-119
2 Burges, R. and Moisey, D. (1994). Unique pharmacologic properties of amlodipine. Am. J. Cardial. 73, 2A-9A   DOI   ScienceOn
3 Cangiano, J. L., Rodriguez-Sargent, C. and Martinez-Maldonado, M. (1979). Effects of antihypertensive treatment on systolic blood pressure and renin in experimental hypertension in rats. J. Pharmacal. Exp. Ther. 208, 310-313
4 Cauvin, C., Loutzenhiser, R. and Van Breemen C. (1983). Mechanisms of calcium antagonist-induced vasodilation. Annu. Rev. Pharmacal. Toxical. 23, 373-396   DOI   ScienceOn
5 Dodd, M. G., Gardiner, D. G., Carter, A. J., Sutton, M. R. and Burges, R. A. (1989). The hemodynamic properties of amlodipine in anesthetised and conscious dogs: comparison with nitrendipine and influence of beta-adrenergic blockade. Cardiovasc. Drugs Ther. 3, 545-555   DOI
6 Mathur, S., Syme, H., Brown, C. A, Elliot, J., Moore, P. A, Newell, M. A, Munday, J. S., Cartier, L. M., Sheldon, S. E. and Brown, S. A (2002). Effects of the calcium channel antagonist amlodipine in cats with surgically induced hypertensive renal insufficiency. Am. J. Vet. Res. 63, 833-839   DOI   ScienceOn
7 Meredith, P. A and Elliott, H. L. (1992). Clinical pharmacokinetics of amlodipine. Clin. Phannacokinet. 22,22-31   DOI   ScienceOn
8 Stopher, D. A., Beresford, A. P., Macrae, P. V. and Humphrey, M. J. (1988). The metabolism and pharmacokinetics of amlodipine in humans and animals. J. Cardiovasc. Pharmacol. 12, S55-S59   DOI
9 Phillips, R. A., Kloner, R. A., Grimm, R. H. Jr. and Weinberger, M. (2003). The effects of amlodipine compared to losartan in patients with mild to moderately severe hypertension. J. Clin. Hypertens. (Greenwich) 5, 17-23
10 Shin, H. S., Seo, H. W., Yoo, S. E. and Lee, B. H. (1998). Cardiovascular pharmacology of SKP-450, a new potassium channel activator, and its major metabolites SKP-818 and SKP-310. Phannacology 56, 111-124
11 Abernethy, D. R. (1989). The pharmacokinetic profile of amlodipine. Am. Heart J. 118, 1100-1103   DOI   ScienceOn
12 Lee, B. H., Seo, H. W., Yoo, S. E., Kim, S. O., Lim, H. and Shin, H. S. (2001). Differential action of KR-31378, a novel potassium channel activator, on cardioprotective and hemodynamic effects. Drug Dev. Res. 54, 182-190   DOI   ScienceOn
13 Lee, B. H. and Shin, H. S. (1994). In vivo pharmacological evaluation of newly synthesized nonpeptidic AT1 receptor antagonists in rats. Arch. Pharm. Res. 17, 263-268   DOI
14 Lee, B. H., Yoo, S. E. and Shin, H. S. (1998). Hemodynamic profile of SKP-450, a new potassium-channel activator. J. Cardiovase. Pharmacol. 31, 85-94   DOI   ScienceOn
15 Lee, B. H., Seo, H. W., Kwon, K. J., Yoo, S. E. and Shin, H. S. (1999). In vivo pharmacologic profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist. J. Cardiovasc. Phannacol. 33, 375-382   DOI   ScienceOn
16 Yamanaka, K., Suzuki, M., Munehasu, S. and Ishiko, J. (1991). Antihypertensive effects of amlodipine, a new calcium antagonist. Nippon Yakurigaku Zasshi 97, 115-126   DOI   ScienceOn